Seeking Alpha

GlaxoSmithKline (GSK +0.5%) and Theravance (THRX -1.7%) say their New Drug Application for...

GlaxoSmithKline (GSK +0.5%) and Theravance (THRX -1.7%) say their New Drug Application for UMEC/VI, a treatment for patients with chronic obstructive pulmonary disease, has been accepted by the FDA, giving it the go-ahead for a substantive review. The PDUFA goal date has also been set for December 18, 2013.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector